268 related articles for article (PubMed ID: 29468311)
1.
Thomas L; Kantz S; Hung A; Monaco D; Gaertner FC; Essler M; Strunk H; Laub W; Bundschuh RA
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1170-1178. PubMed ID: 29468311
[TBL] [Abstract][Full Text] [Related]
2. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
3. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using
Zamboglou C; Sachpazidis I; Koubar K; Drendel V; Wiehle R; Kirste S; Mix M; Schiller F; Mavroidis P; Meyer PT; Werner M; Grosu AL; Baltas D
Radiother Oncol; 2017 Jun; 123(3):472-477. PubMed ID: 28499607
[TBL] [Abstract][Full Text] [Related]
5. Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
Chang JH; Lim Joon D; Lee ST; Gong SJ; Anderson NJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e691-6. PubMed ID: 22658218
[TBL] [Abstract][Full Text] [Related]
6. Inverse and forward optimization of one- and two-dimensional intensity-modulated radiation therapy-based treatment of concave-shaped planning target volumes: the case of prostate cancer.
Corletto D; Iori M; Paiusco M; Brait L; Broggi S; Ceresoli G; Iotti C; Calandrino R; Fiorino C
Radiother Oncol; 2003 Feb; 66(2):185-95. PubMed ID: 12648791
[TBL] [Abstract][Full Text] [Related]
7. Is SBRT Boost Feasible for PET Positive Lymph Nodes for Cervical Cancer? Evaluation using Tumor Control Probability and QUANTEC Criteria.
Snyder JE; Willett AB; Sun W; Kim Y
Pract Radiat Oncol; 2019 Mar; 9(2):e156-e163. PubMed ID: 30415074
[TBL] [Abstract][Full Text] [Related]
8. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
9. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
Dewes S; Schiller K; Sauter K; Eiber M; Maurer T; Schwaiger M; Gschwend JE; Combs SE; Habl G
Radiat Oncol; 2016 May; 11():73. PubMed ID: 27229485
[TBL] [Abstract][Full Text] [Related]
10. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer.
Seppälä J; Seppänen M; Arponen E; Lindholm P; Minn H
Radiother Oncol; 2009 Nov; 93(2):234-40. PubMed ID: 19766336
[TBL] [Abstract][Full Text] [Related]
11. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost.
Pinkawa M; Holy R; Piroth MD; Klotz J; Nussen S; Krohn T; Mottaghy FM; Weibrecht M; Eble MJ
Strahlenther Onkol; 2010 Nov; 186(11):600-6. PubMed ID: 20936457
[TBL] [Abstract][Full Text] [Related]
12. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
[TBL] [Abstract][Full Text] [Related]
13. The impact of [
Frenzel T; Tienken M; Abel M; Berliner C; Klutmann S; Beyersdorff D; Schwarz R; Krüll A; Bannas P
Strahlenther Onkol; 2018 Jul; 194(7):646-654. PubMed ID: 29572670
[TBL] [Abstract][Full Text] [Related]
14. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.
Riches SF; Payne GS; Desouza NM; Dearnaley D; Morgan VA; Morgan SC; Partridge M
Br J Radiol; 2014 May; 87(1037):20130813. PubMed ID: 24601648
[TBL] [Abstract][Full Text] [Related]
15. Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy.
Nutting CM; Corbishley CM; Sanchez-Nieto B; Cosgrove VP; Webb S; Dearnaley DP
Br J Radiol; 2002 Feb; 75(890):151-61. PubMed ID: 11893639
[TBL] [Abstract][Full Text] [Related]
16. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost.
Pinkawa M; Attieh C; Piroth MD; Holy R; Nussen S; Klotz J; Hawickhorst R; Schäfer W; Eble MJ
Radiother Oncol; 2009 Nov; 93(2):213-9. PubMed ID: 19717197
[TBL] [Abstract][Full Text] [Related]
17. Effect of androgen deprivation therapy on intraprostatic tumour volume identified on
Chan J; Carver A; Brunt JN; Vinjamuri S; Syndikus I
Br J Radiol; 2017 Mar; 90(1071):20160818. PubMed ID: 27993093
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
19. A study of the effects of internal organ motion on dose escalation in conformal prostate treatments.
Happersett L; Mageras GS; Zelefsky MJ; Burman CM; Leibel SA; Chui C; Fuks Z; Bull S; Ling CC; Kutcher GJ
Radiother Oncol; 2003 Mar; 66(3):263-70. PubMed ID: 12742265
[TBL] [Abstract][Full Text] [Related]
20. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
